Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


June 18-20, 2019
Park Central Hotel,
San Francisco, CA

The Definitive Event Revolutionizing Cell Line Development through Disruptive Techniques and Innovative Science

Practical solutions to reduce development timelines, increase efficiencies, improve product quality, and realize greater productivity from new and established cell lines

The Trusted Event by Industry and Academia Alike

Where the bioproduct development community gathers to investigate
  • Developments in host cell engineering to improve quality and growth
  • Application in genome editing in cell  line development
  • Demonstrating and questioning the importance of clonality
  • Acceleration of early development
  • Cell line & host cell engineering technologies
  • High throughput platforms for cell line development
Three days of case studies, new/unpublished data, challenges and solutions

All delivered in a dedicated, open environment that provides practical knowledge and new solutions for teams from across industry, academia and research organizations.

New and Extended Sessions for 2018!
  • Advances in genome editing technologies--updated information on CRISPR and information on regulations
  • Regulatory feedback and insight
  • -Omics in cell line development
  • Cell line considerations for bioprocessing
  • Clonality and stability in cell line development

The Leading Cell Line Development Meeting

Meet, learn and network with over 250 scientists and academics
Over 25 New Data Sessions to Attend Across the Event
Hours of Dedicated Networking

Get Answers Now

  • Are there constraints for commercial human therapeutic applications of gene editing, given the current IP landscape? 
  • How important is the outcome of the patent interference (UC – U of Vienna vs. “Boston Biotech Cluster”) to the future of gene editing?
  • Are there uncertainties in translational research and clinical trials due to broad exclusive licenses over CRISPR technologies IP? 
  • Is CRISPR genome-editing know-how going to define future applications and further developments of it as nonobvious? 
  • Will commercial sublicenses be needed for follow-on applications of CRISPRC as technology? If so, when is this going to happen?

Present a Scientific Poster!

Share your company's new research by presenting a poster at Cell Line Development & Engineering.  All posters are displayed in the Poster & Exhibit Hall throughout the event.

Please note that all poster presenters must be registered attendees.  The deadline to submit your abstract is May 28, 2018.

Sponsorship & Exhibition Opportunities

Showcase the adaptability of your products to leading scientists representing the upstream development and bioprocessing chain, spanning early stage discovery to early stage development.

For more information or to begin building your custom sponsorship package today, contact Kristin Skahan at (857) 504-6730 or